In the first hearing held on 13 Jan ’12 on Natco’s CL application for Sorafenib (generic version of Bayer’s Nexaver), the Controller General of Patents had asked Bayer, German drug maker to submit cost data, including research and development expenditure on Nexavar to justify the substantially high price. Click here to read more about the case hearing reported by Livemint.
The second hearing will take place next month. Bayer had argued that it is not possible for it to sell the drug at a lower cost as the investment made on the drug cant be recovered with the price lower than the one currently being offered. Bayer sell Nexaver at the cost of Rs. 2.8 lacks per month.
See a graphical representation of the stark difference between the price being offered for this drug by Bayer (originator company) and the two generics (Cipla & Natco) in India.
See our earlier posting on this issue here
Pingback: Bayer Asked to Disclose R&D Cost Data for Anticancer Drug